Cumberland Pharmaceuticals 3Q 2026: Revenue $2.16M, EPS $5.07 — 10-Q Summary

Cumberland Pharmaceuticals reported 3Q 2026 revenue of $2.16M, up 1155% YoY, driven by transition services revenue. Net income was $77.78M, swinging to profit from a loss, with EPS at $5.07. The company completed a $100M Apotex transaction and is advancing its Ifetroban pipeline.

Original reporting
Published Nov 13, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cumberland Pharmaceuticals 3Q 2026: Revenue $2.16M, EPS $5.07 — 10-Q Summary — source image
Decision brief

The 30-second read

$CPIXBullishMed
01

Why it matters

The surprise profit could trigger a short‑term rally, but investors should assess the durability of the underlying business.

02

Market read

Earnings surprise for a micro‑cap biotech; may attract speculative buying.

03

What to watch

Sustaining revenue after the Apotex transaction remains uncertain; pipeline progress is still early.

Relevance 7/10Novelty 7/10Timing: after-hours filing

Background

Cumberland Pharmaceuticals filed its Q3 2026 10‑Q, showing a dramatic earnings swing after a $100M Apotex sale and a disposal gain.

Company-level read

Ticker impact

$CPIXBullishMedium confidence
Context

Cumberland Pharmaceuticals reported Q3 2026 revenue of $2.16M and a surprise profit of $77.78M in its 10‑Q filing.

Expected impact

upward pressure as market prices in the unexpected profit and revenue growth.

Evidence & confidence

The company posted a large profit swing from a loss, driven by a $81.1M disposal gain and higher interest income, which is material for a micro‑cap.

Market effects

Highlights potential upside for small‑cap pharma stocks with asset disposals and transaction‑driven revenue.

Limited to U.S. micro‑cap biotech segment.

Low global relevance; primarily affects niche investors.

Counterpoint

The profit is largely one‑off from asset disposal; future earnings may revert to loss.

Key entities

  • Cumberland Pharmaceuticals

    Micro‑cap pharma firm reporting Q3 2026 results.

Related articles

$CPIXMedAI 8/10

Cumberland Pharmaceuticals Q3 Earnings Call Highlights

Cumberland Pharmaceuticals (CPIX) reported Q3 earnings, including a $108M net funding estimate from a transaction, a $1.50 special dividend, and share repurchase plans. The company projects cash to fund operations for over five years. Cumberland is preparing a new drug application for ifetroban to treat Duchenne muscular dystrophy, with FDA rolling review granted. The company also discussed other clinical programs and retained majority ownership of Cumberland Emerging Technologies.

$CPIXHighAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE $100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland

$CPIXMedAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals (CPIX) reported Q3 2026 results, highlighting a $100M strategic transaction and plans to submit an NDA for ifetroban to treat DMD-related cardiomyopathy. The company also announced positive top-line results from a systemic sclerosis trial. Cumberland's net income was $77.8M, with $80.6M in cash reserves. The company is focusing on developing new therapies for rare diseases.

$CPIXMedAI 8/10

Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy

Cumberland Pharmaceuticals (CPIX) has begun a rolling FDA NDA submission for Dyscorban to treat Duchenne cardiomyopathy. The FDA previously requested additional data, which the company plans to provide. Cumberland reported positive safety data from clinical studies and holds regulatory designations for the program. The company expects its balance sheet to fund development and NDA submission.

$CPIXHighAI 8/10

Cumberland plans NDA filing for DMD cardiomyopathy treatment

Cumberland Pharmaceuticals (CPIX) plans to submit a New Drug Application for ifetroban to treat cardiomyopathy in Duchenne muscular dystrophy. The FDA granted a rolling review. The FIGHT DMD trial showed a 5.4% improvement in left ventricular ejection fraction. The FDA requested additional analysis. Ifetroban has Orphan, Rare Pediatric, and Fast Track designations.